What is the best strategy for reducing deaths from heart disease?

PLoS Medicine

Volumn 2, Issue , 2005, Pages 0272-0276

  Makover, Michael E ^a   Ebrahim, Shah ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ARTERIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CAUSE OF DEATH; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ECHOGRAPHY; HEALTH CARE POLICY; HEART DISEASE; HIGH RISK PATIENT; HUMAN; LIFESTYLE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; ARTICLE; COST BENEFIT ANALYSIS; INTIMA; PATIENT CARE PLANNING;

ATHEROSCLEROSIS; CAROTID ARTERIES; COST-BENEFIT ANALYSIS; HEART DISEASES; HUMANS; PATIENT CARE PLANNING; RISK ASSESSMENT; TUNICA INTIMA;

EID: 19344374763     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020098     Document Type: Review

References (28)

1. National Heart, Lung and Blood Institute (2002) Framingham heart study. Available: http://www.nhlbi.nih.gov/about/framingham/index.html. Accessed 26 November 2004.
2. European Society of Cardiology (2004) HeartScore: The new standard in European CVD risk prediction and management. Available at: http://www. escardio.org/knowledge/decision_tools/heartscore/. Accessed 26 November 2004.
3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
4. Libby P (2002) Atherosclerosis: The new view. Sci Am 286: 46-55.
5. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291: 1071-1080.
6. (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3145-3421.
7. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, et al. (2004) Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. circulation.109 (23 Suppl 1): III33-III38.
8. Mancini GB, Dahlof B, Diez J (2004) Surrogate markers for cardiovascular disease: Structural markers. Circulation 109 (25 Suppl 1): IV22-IV30.
9. Anderson KM, Wilson PW, Odell PM, Kannel WB (1991) An updated coronary risk profile. A statement for health professionals. Circulation 83: 356-362.
10. Rose G (2001) Sick individuals and sick populations. Int J Epidemiol 30: 427-432.
11. Eisenberg L (1984) Rudolf Ludwig Karl Virchow, where are you now that we need you? Am J Med 77: 524-532.
12. Department of Health (2004 November) Choosing health: Making healthier choices easier. CM 6374. London: The Stationary Office. 207 p.
13. Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Public Health Paper Number 34. Geneva: World Health Organization.
14. Frankel S, Davey Smith G, Donovan J, Neal D (2003) Screening for prostate cancer. Lancet 361: 1122-1128.
15. Ebrahim S, Davey Smith G (1997) A systematic review and meta-analysis of randomized controlled trials of health promotion for prevention of coronary heart disease in adults. Br Med J 314: 1666-1674.
16. Montgomery A, Fahey T, Brindle P, Davey Smith G, Ebrahim S (2994) Coronary risk scores. Lancet 363: 572-573.
17. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601-1610.
18. Iglesias del Sol A, Moons K, Hollander M, Hofman A, Koudstaal PJ, et al. (2001) Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke 32: 1532-1538.
19. Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, et al. (2003) Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 56: 880-890.
20. Wald N, Law M (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419.
21. Emberson J, Whincup PH, Morris R, Walker M. Ebrahim S (2004) Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 25: 484-491.
22. Lawlor DA, Ebrahim S, Davey Smith G (2001) Sex matters: Secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 323: 541-545.
23. Enos WF, Holmes RH, Beyer JC (1953) Coronary disease among United States soldiers killed in action in Korea; preliminary report. JAMA 152: 1090-1093.
24. McNamara J, Molot M, Stremple J, Cutting R (1971) Coronary artery disease in combat casualties in Vietnam. JAMA 216: 1185-1187.
25. Barker DJP (1998) Mothers, babies and health in later life, 2nd ed. Edinburgh: Churchill Livingstone. 217 p.
26. Kuh D, Ben-Shlomo Y, editors (1997) A life course approach to chronic disease epidemiology. Oxford: Oxford University Press. 317 p.
27. Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, et al. (1999) Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women. The British Regional Heart Study. Stroke 30: 841-850.
28. Mancini GBJ, Abbott D, Kamimura C, Yeoh E (2004) Validation of a new ultrasound method for the measurement of carotid artery intima medial thickness and plaque dimensions. Can J Cardiol 20: 1355-1359.